Quoin Pharmaceuticals (QNRX) risk factors

56 risks, 9 new, 3 dropped, 7 reworded since the prior year. Accumulated deficit grew to $71.0 million by December 31, 2025, raising going concern doubts.

50 risks. Quoin Pharmaceuticals faces heavy clinical and regulatory risks with an accumulated deficit of $55.2 million and no commercial revenue. The company relies entirely on third-party manufacturers, suppliers, and clinical trial contractors for its drug candidates. Operations are governed by Israeli law, adding cross-border corporate and acquisition complexities.